Shedding Light on the Role of Neurotransmitters in the Microenvironment of Pancreatic Cancer

Yiyi Liang†, Huimin Li†, Yu Gan* and Hong Tu*

State Key Laboratory of Oncogenes and Related Genes, Shanghai Institute of Life Science, Shanghai, China

Pancreatic cancer (PC) is a highly lethal malignancy with a 5-year survival rate of less than 8%. The fate of PC is determined not only by the malignant behavior of the cancer cells, but also by the surrounding tumor microenvironment (TME), consisting of various cellular (cancer cells, immune cells, stromal cells, endothelial cells, and neurons) and non-cellular (cytokines, neurotransmitters, and extracellular matrix) components. The pancreatic TME has the unique characteristic of exhibiting increased neural density and altered microenvironmental concentration of neurotransmitters. The neurotransmitters, produced by both neuron and non-neuronal cells, can directly regulate the biological behavior of PC cells via binding to their corresponding receptors on tumor cells and activating the intracellular downstream signals. On the other hand, the neurotransmitters can also communicate with other cellular components such as the immune cells in the TME to promote cancer growth. In this review, we will summarize the pleiotropic effects of neurotransmitters on the initiation and progression of PC, and particularly discuss the emerging mechanisms of how neurotransmitters influence the innate and adaptive immune responses in the TME in an autocrine or paracrine manner. A better understanding of the interplay between neurotransmitters and the immune cells in the TME might facilitate the development of new effective therapies for PC.

Keywords: pancreatic cancer, tumor microenvironment (TME), neurotransmitter, immunotherapy, immune cells

INTRODUCTION

Although the accumulation of genetic and epigenetic defects is believed to drive carcinogenesis, the progression of cancer is indeed highly dependent on the interactions between cancerous and non-cancerous cells in the tumor microenvironment (TME). Immune cells make a large contribution to the non-malignant cellular components in the TME (Ho et al., 2020). Tumor-infiltrated immune cells bring out an important and complicated regulatory function in cancer progression. The TME also includes multiple secreted non-cellular components, such as cytokines, neurotransmitters and extracellular matrix (Dey et al., 2020; Winkler et al., 2020). Among them, neurotransmitters are recently emerging as a novel non-cellular portion of the TME that have been appreciated in cancer progression, especially in pancreatic cancer (PC) (Tan et al., 2021).
Information transduction, while inhibitory neurotransmitters activate the postsynaptic neuron and facilitate interneuronal or neuromodulator. Excitatory neurotransmitters (such as NE) their function (excitatory or inhibitory) or by their action (direct and many others. Also, neurotransmitters can be classified by neuropeptide Y (NPY), calcitonin gene related peptide (CGRP) acid (GABA), glycine, glutamate, histamine, and acetylcholine. Amino acid neurotransmitters contain gamma-aminobutyric amine neurotransmitters are composed of dopamine (DA), amines, amino acids, peptides, and other categories. Biogenic chemicals structure, the critical classification of neurotransmitters can be summarized as follows (Spitzer, 2015): biogenic amines, amino acids, peptides, and other categories. Biogenic amine neurotransmitters are composed of dopamine (DA), norepinephrine (NE), epinephrine (E), and serotonin (5-HT). Amino acid neurotransmitters contain gamma-aminobutyric acid (GABA), glycine, glutamate, histamine, and acetylcholine (Ach). Peptide neurotransmitters contain substance P (SP), neuropeptide Y (NPY), calcitonin gene related peptide (CGRP) and many others. Also, neurotransmitters can be classified by their function (excitatory or inhibitory) or by their action (direct or neuromodulator). Excitatory neurotransmitters (such as NE) activate the postsynaptic neuron and facilitate interneuronal information transduction, while inhibitory neurotransmitters (such as GABA) inhibit the postsynaptic neuron and hinder information transduction. Some neurotransmitters can be both excitatory and inhibitory. Neuromodulators (such as 5-HT and DA) do not directly participate in interneuronal information transduction, but work together with excitatory or inhibitory neurotransmitters to modify the postsynaptic cell’s response (Boto and Tomchik, 2019). Differ from neuromodulators in the extent of actions, neurohormones (such as oxytocin and vasopressin) are secreted by neurosecretory cells into the blood steam and exert their effect on distant peripheral targets (Iovino et al., 2019).

Emerging evidence demonstrates that neurotransmitters can be released not only by the neurons from the central or peripheral nervous system, but also by non-neuronal cells (Table 1). For instance, Ach, the first established neurotransmitter, has been found to be synthesized in a variety of non-neuronal cells such as epithelial cells (from airway, digestive tract, urogenital tract, or epidermis), mesothelial cells (from pleura or pericardium), endothelial cells, fat cells, and fibroblasts (Reijmen et al., 2018; Elyada et al., 2019). The primary and secondary lymphatic organs of the immune system can be innervated by nerves. The local neurotransmitter thus can act as an immunomodulatory messenger to regulate the interaction between peripheral nerves and the lymphocytes (Zhang et al., 2014; Blanchart et al., 2017; Sung et al., 2017; Hujber et al., 2018). This peripheral innervation has been reported to participate in the development of immune cells (Allen et al., 2020). Meanwhile, the immune cells can also produce specific neurotransmitters such as 5-HT (Chen et al., 2015) to regulate the immune cells function and remodel the surrounding microenvironment through autocrine and paracrine approaches (Briggs et al., 2016).

In the nervous system, neurotransmitters mediate interneuronal communication in synaptic transmission. Although whether nerve-to-non-neuronal cell synapses or synapse-like structures exist outside of the nervous system is not yet known, the nervous system can influence non-neuronal cells through changing circulating neurotransmitter levels (Monje et al., 2020). In the tumor microenvironment, neurotransmitters may be also secreted from non-neuronal cells and confer both paracrine and autocrine effects on cancer cells, as well as immune cells.

**The Role of Neurotransmitters in Cancer**

Similar to the process of neovascularization and lymphangiogenesis, the formation of new nerve endings in the tumor is called neurogenesis. Neurogenesis is one of the determinants in tumorigenesis and cancer development (Boilly et al., 2017). Neurotransmitters serve as a link between intratumoral nerves and tumor cells in the TME. Tumor cells express various neurotransmitter receptors. Neurotransmitters released from nerve fibers in the TME can directly act on tumor cells by binding to their specific neurotransmitter receptors (Hanoun et al., 2015; Renz et al., 2018a,b). Meanwhile, tumor cells can also produce endogenous neurotransmitters in response to diverse stimuli from the microenvironment. For example, various types of tumor cells have been revealed to produce GABA. The elevated intratumoral level of GABA has been...
Neurotransmitters in TME of PC

TABLE 1 | The origin of neurotransmitters.

| Neurotransmitters | Non-neuronal secretion | References |
|-------------------|-------------------------|------------|
| Norepinephrine    | Thymic cells            | Roggero et al., 2011; McBurney-Lin et al., 2019 |
| Serotonin         | Enterochromaffin (EC) cells of the gastrointestinal tract, thymic epithelial cells, cancer cells, immune cells, platelet | Lifantseva et al., 2017; Spoohn and Mawe, 2017 |
| Dopamine          | Gastrointestinal tract, thymic epithelial cells, immune cells | Lifantseva et al., 2016; Liu C. et al., 2021 |
| GABA              | Cancer cells, the endocrine cells of pancreatic islets | Soltani et al., 2011; Kim et al., 2015 |
| Substance P       | Enterochromaffin (EC) cells of the gastrointestinal tract, thymic epithelial cells | Heitz et al., 1976; Zaidi and Matthews, 2013 |
| NPY               | Cancer cells            | Gotzsche and Woldbye, 2016 |
| CGRP              | Immune cells            | Bracci-Laudero et al., 2002; Messlinger, 2018 |
| Acetylcholine      | Epithelial cells, immune cells, cancer cells | Brenner and Sainmann, 1978; Kawashima and Fuji, 2004 |
| Histamine         | Mast cells              | Haas et al., 2008; Misto et al., 2019 |
| Glutamate         | Endocrine cells of pancreatic islets | Cabrera et al., 2006 |

observed in PC as well as ovarian cancer and breast cancer (Zhang et al., 2014; Jiang et al., 2019).

Neurotransmitters can affect almost all aspects related to tumor development including cell proliferation, angiogenesis, and metastasis (Boilly et al., 2017). Peripheral 5-HT generates a mitotic effect on a variety of tumor and non-tumor cells such as fibroblasts, smooth muscle cells, osteoblasts, mesangial cells, and endothelial cells (Alpini et al., 2008; Moon et al., 2020). Many studies have shown a potential stimulatory effect of 5-HT on cancer cell proliferation, invasion, dissemination, and tumor angiogenesis (Herr et al., 2017). Abnormal glutamate signaling showed carcinogenic potential in glioma, melanoma, breast cancer, and prostate cancer (Ribeiro et al., 2017; Sung et al., 2017; Yu et al., 2017; Anastas and Shi, 2019). Substance P and SP/NK-1 system have also been involved in the development and progression of many cancers such as glioma, colon cancer, and lung cancer (Munoz et al., 2011; Covenas and Munoz, 2014). Elucidating their specific roles in tumor biology especially in the TME may open up new windows for the diagnosis and treatment of cancers.

NEUROTRANSMITTERS IN THE TME OF PANCREATIC CANCER

Nerves and Neurotransmitters Are Key Components of Pancreatic TME

The TME of pancreatic cancer is characterized by nutrient deficiency, connective tissue hyperplasia and high nerve distribution. Paracrine signals derived by cancer cell promote nerve axonogenesis or neurogenesis in the TME. The infiltrated nerve fibers can control cancer initiation, growth and metastasis. Nerve fibers in the pancreatic TME include axons originating from the sympathetic, parasympathetic, enteropancreatic or hepatic plexus, afferent nerve fibers and newly developed nerve fibers. Neuron as presynaptic cell can secrete neurotransmitters such as E/NE, which act on specific receptors to regulate tumor proliferation and metastasis. In PC cells, sensory (Saloman et al., 2016; Sinha et al., 2017) and sympathetic nerves activate the growth of PC cells through the liberation of substance P and E/NE. On the contrary, parasympathetic nerves inhibit PC cell growth via ACh, leading to the inhibition of PI3K/ Akt and EGFR/ERK in cancer cell (Renz et al., 2018b). This opposite impact of sympathetic and parasympathetic nerves suggests that the development of PC is regulated through a balance of neural innervation.

Neural remodeling and PNI are important pathological characteristics of PC (Guo et al., 2013). Neural remodeling is manifested as the increased size and density of infiltrated nerves in the pancreas. PNI is considered as one of the main routes for PC recurrence and metastasis after surgical resection since it presents a structural conduit for cell migration. Recent studies have illustrated that multiple types of cells in the TME of PC contribute to neural remodeling and PNI (Li et al., 2014). New nerve fibers in the TME act as a rich source of neurotransmitters and neurotrophic factors (Zahalka and Frenette, 2020), which substantially affects the malignant potential of tumor cells and the disease progression. For example, the classical neurotransmitters NE and 5-HT have been found to be significantly increased in PC tissues (Zhao et al., 2014; Jiang et al., 2017), and the altered levels of different neurotransmitters have been demonstrated to be associated with PC recurrence, metastasis, and survival (Guo et al., 2013), suggesting that microenvironmental neurotransmitters function as an essential non-cellular component that contributes to PC progression (Schuller et al., 2012).

Direct Effects of Neurotransmitters on Pancreatic Cancer

Neurotransmitters in the TME can be released by tumor-infiltrating fibers, cancer cells and non-cancerous cells such as immune cells and epithelial cells (Entschladen et al., 2008; Boilly et al., 2017). Neurotransmitters have numerous regulatory functions on PC cells, which we summarized in Table 2.

Epinephrine and Norepinephrine

The classical neurotransmitters E and NE have been found to give promotion to PC progression through multiple mechanisms. E and NE are stress molecules produced by the sympathetic nervous system and linked to PC growth via β-adrenergic signaling in both in vitro and in vivo studies (Renz et al., 2018b). Specifically, E indirectly enhanced β-AR-dependent neurotrophin secretion, which in turn increased NE levels and promoted PC growth (Zhao et al., 2014). The activation of β-AR can promote tumor growth and angiogenesis via VEGF and metalloproteinase MMP2/MMP9 signaling pathways (Thaker et al., 2006). NE also tended to promote...
PC progression through β-AR/PKA/STAT3 signaling pathway (Coelho et al., 2017).

**Serotonin**

The neurotransmitter 5-HT, as well as its receptors, was found to be elevated in PC tissues (Jiang et al., 2017). Knockdown of 5-HT receptors inhibited the proliferation and invasion of human PC cells in vitro (Gurbuz et al., 2014). In contrast, the activation of 5-HT receptors enhanced glycolysis under metabolic stress, and thus promoted the growth of PC. Regarding to its molecular mechanism, 5-HT stimulation increased the Warburg effect through PI3K-Akt-mTOR signaling (Jiang et al., 2017). In addition, the increased levels of type 1 tryptophan hydroxylase (TPH1), which was a key enzyme for peripheral 5-HT synthesis, and the decreased level of MAOA, which is responsible for 5-HT degradation, in PC tissues were correlated with the poor survival of patients (Jiang et al., 2017). Of importance, the metaplasia of acinar-to-ductal metaplasia (ADM) is a key determinant in PC development (Liou et al., 2017). Serotonin uptake by acinar cells could promote the activation of the small GTPase Ras-related C3 botulinum toxin substrate 1 (Rac1), which is required for the transdifferentiation of acinar cells into ADM (Saponara et al., 2018).

**Dopamine**

The effect of DA on cancer cells is tumor type-specific. DA mainly reduced the proliferation and migration of endothelial cells in TME (Hoeppner et al., 2015). In PC, the dopamine receptor D2R is abnormally highly expressed and the antagonists of D2R (pimozide and haloperidol) were able to prevent the proliferation of PC cells, suggesting a PC-promoting effect of DA (Jandaghi et al., 2016).

**Gamma-Aminobutyric Acid**

Gamma-Aminobutyric Acid (GABA) is a major inhibitory neurotransmitter in the central nervous system (CNS). Different GABA receptors play different roles in tumor growth. GABA was found to enhance prostate cancer cell proliferation through the GABA-A receptor pathway (Blanchart et al., 2017) and to inhibit angiogenesis and migration of pancreatic cancer cells (Qian et al., 2018). In PC, the dopamine receptor D2R is abnormally highly expressed and the antagonists of D2R (pimozide and haloperidol) were able to prevent the proliferation of PC cells, suggesting a PC-promoting effect of DA (Jandaghi et al., 2016).
liver cancer (Wang et al., 2008; Hujber et al., 2018). GABRP, a subunit of the GABA-A receptor, was abnormally highly expressed in PC cells (Jiang et al., 2019). GABA treatment in GABRP-positive PC cells increased intracellular Ca\(^{2+}\) levels and activated the MAPK/Erk cascade, which led to a pro-tumor effect on PC (Takehara et al., 2007).

**Neuropeptides**

Neuropeptides, such as substance P, CGRP, and NPY, were also found to have a direct effect on PC cells. Substance P was a powerful regulator to PNI in PC during the early stage of primary tumor formation via the MMP1/PAR1/SP/NK-1R paracrine loop (Huang et al., 2018). Besides, substance P induced cancer cell proliferation and invasion as well as the expression of MMP-2 in PC cells, and sensory nerves in TME may help PC progression in part through up-regulation of its receptor (Sinha et al., 2017). Human PC cells possess distinct CGRP receptors. CGRP can stimulate the proliferation of human PC cells, suggesting a role of CGRP in the growth of PC cells (Zhou, 1993). What’s more, CGRP and substance P derived from pancreatic stellate cells mediated the PC pain via activation of sHH signaling pathway (Han et al., 2016), which provided a novel therapeutic option for PC pain. NPY could be detected in both human and murine pancreatic samples. Its receptor Y2 was significantly increased in PanIN lesions and PC samples both in murine and human. The enhanced Y2 receptor-mediated NPY signaling may modulate the angiogenesis of PC (Waldmann et al., 2018).

**Effects of Neurotransmitters on Non-malignant Cells in Pancreatic TME**

In addition to affecting tumor cells, neurotransmitters can also improve angiogenesis, lymphangiogenesis, and inflammatory responses via exerting influence on endothelial cells and stromal cells in the TME. For instance, the activation of β-AR (β2 and β3) expressed on stromal cells promotes the survival of prostate cancer cells via TGF-β signaling (Magnon et al., 2013). Neovascularization is a vital process involved in tumor growth and metastasis. There is substantial evidence indicating that vascular endothelium infiltrated in the TME expresses various neurotransmitter receptors such as E and NE (Sarkar et al., 2013). NE could also stimulate endothelial cell metabolism and drive angiogenesis in tumors (Zahalka et al., 2017; Hondermarck and Jobling, 2018). DA was shown to mobilize endothelial progenitor cells from the bone marrow and participate in angiogenesis in the TME (Chakroborty et al., 2008). Neuropeptide Y released by tumor cells interacts with receptors on endothelial cells or immune cells, modulating tumor-related angiogenesis and local inflammatory responses (Medeiros and Jackson, 2013). Meanwhile, neurotransmitters can also regulate stromal cells in the microenvironment. Using a high-throughput drug screening system that focuses on the pancreatic stellate cells, Sagara et al. found that dopamine antagonist could inhibit the activation of pancreatic stellate cells and suppressed the invasion of pancreatic cancer cells by disrupting tumor-stromal interaction (Sagara et al., 2021). In addition, 5-HT was demonstrated to be essential for the survival and activation of hepatic stellate cells. Serotonin-activated stellate cells could promote carcinogenesis and contribute to sex disparity in hepatic cell carcinoma (Yang et al., 2017).

**INTERPLAYS BETWEEN NEUROTRANSMITTERS AND THE IMMUNE CELLS IN PANCREATIC TME**

**Immune Cells in the TME of Pancreatic Cancer**

Intratumoral immune heterogeneity is considered as a hallmark feature of the TME (Riggan et al., 2021). The tumor immune microenvironment has an immense influence on tumor initiation, progression and therapeutic response. Immune effector cells such as CD8\(^{+}\) cytotoxic T cells (CTL) and natural killer (NK) cells infiltrated in the TME keep the malignant cells under surveillance and form “barriers” to restrain cancer cell metastasis (Kurtulus et al., 2019). The secretion of multiple cytokines in pancreatic TME effect T helper (TH) cells, especially switching the balance of TH1/TH2, and contribute to the immunosuppressive microenvironment (Ho et al., 2020). Dendritic cells (DCs) are also considered as a significant component in adaptive anti-tumor immunity. DCs get involved in the proliferation of CTL in the TME (Puleo et al., 2018; Binnewies et al., 2019; Wculek et al., 2020) due to their role in tumor antigen recognition and presentation that stimulates T cell activation.

On the other hand, the TME can provide an immunosuppressive niche to negatively regulate immune effector cells and facilitate the malignant progression of cancer (Ho et al., 2020), and causes the resistance of PC against various treatments such as chemotherapy, targeted therapy, and immunotherapy (Balachandran et al., 2019). The major immunosuppressive cell types in the TME of pancreatic cancer are tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), regulatory T cells (Treg), TH17, and tolerogenic DCs (Bronte and Tortora, 2016; Zhu et al., 2017; Ligorio et al., 2019; Zhang et al., 2020). These immunosuppressive cells promote tumor progression through a variety of mechanisms, including the direct mediation, inhibition of tumor-killing immune cells, induction of angiogenesis and lymphoangiogenesis (Ho et al., 2020), and promotion of metastasis. TAMs and MDSCs predominate in the TME and continuously communicate with PC cells to propagate disease progression (Lin et al., 2019). TAMs foster immune escape in the TME by suppressing TH1 cell and the antitumor responses of CTL. These contribute to matrix remodeling and facilitate tumor cell migration and invasion and promote tumor angiogenesis and growth (Qian and Pollard, 2010; Binnewies et al., 2018; Halbrook et al., 2019). MDSCs are known to exert immunosuppressive effects on T cells via secreting arginase, nitric oxide synthase, TGF-β, IL-10, and COX2 (Zhang et al., 2017). Tregs suppress tumor immunity in PC through a variety of pathways including the secretion of IL-10, TGF-β, and granzyme B, the activation of the TRAIL pathway and enhancement of T cells’ dysfunction (Zhang et al., 2020). TH17 cells are able to promote tumor cell...
growth by secreting IL-17, IL-23, and CCL20 (Wu H.H. et al., 2015), and inhibit the CD8$^+$ T-mediated immune response by IL-17 and IL-22 (Yan and Richmond, 2020). Tumor-infiltrating lymphocytic B cells (TIL-B) resident in tertiary lymphoid structures were associated with better survival in PC patients, while TIL-B got involved in the initiation and progression of PC (Roghanian et al., 2016; Wouters and Nelson, 2018; Mirlekar et al., 2020).

As more TAMs were found in PC with PNI compared to that without PNI (Li et al., 2014; Alrawashdeh et al., 2019), the infiltration of immunosuppressive cells has been considered to relate to the PNI, which is the prominent characteristic of PC. Being the key molecular mediators of neuroimmune interactions, neurotransmitters might mediate the PNI-induced infiltration of immunosuppressive cells in PC. The PNI of pancreatic cancer could mediate β-AR signaling, and the released Ach enhanced tumor growth by establishing an immune-suppressive TME characterized by impaired CTL infiltration and a reduced TH1/TH2 ratio (Yang et al., 2020).

**Immune Cells as Non-neuronal Sources of Neurotransmitters**

In recent years, promising studies have drawn the attention that immune cells in different activated states can synthesize or store neurotransmitters participate in neuroimmune regulatory circuits (Marino and Cosentino, 2013). Immune cells such as activated TH cells, Treg cells, and mature DC are able to synthesize or release serious classical neurotransmitters and their metabolites, including Ach, DA, and 5-HT. The synthesis of Ach was firstly observed in T cells (Ogawa et al., 2003). Compared with CD8$^+$ T cells or B cells, CD4$^+$ T cells contain more Ach (Kawashima and Fujii, 2003). TH cells could express tyrosine hydroxylase, the rate-limiting enzyme in the synthesis of DA, and store DA in the intracellular vesicles (Cosentino et al., 2000, 2007; Nakano et al., 2009). The inhibitory neurotransmitter such as 5-HT could be secreted by T cells, DCs, and macrophages (O’Connell et al., 2006; Wu et al., 2017).

Of interest, immune cells such as activated T cells have the capacity to synthesize 5-HT, and this potential is enhanced during their activation (O’Connell et al., 2006; Chen et al., 2015). CD8$^+$ T cells were found to selectively express the highest level of type I tryptophan hydroxylase (TPH1), an enzyme that catalyzes the conversion of L-tryptophan (a direct precursor of 5-HT), indicating that they are capable of producing 5-HT. DCs and B cells can accumulate 5-HT through a regulated uptake mechanism from the microenvironment or activated T cells via serotonin transporters (SERTs) (Chen et al., 2015). Specifically, the expression of SERT on the surface of DC cells would increase as DCs matured or activated (Katoh et al., 2006), and also dynamically adjusted with the change level of 5-HT in the microenvironment (Arreola et al., 2015). Once DCs contact with T cells, their SERT expressions would significantly up-regulate (Chen et al., 2015). The stored 5-HT in DCs within LAMP-1$^+$ vesicles were subsequently released via Ca$^{2+}$-dependent exocytosis. Thus, DCs could sequester 5-HT, which are released from the microenvironment or directly from activated T cells, and transmit this 5-HT to naive T cells. This process suppressed CAMP production and thereby facilitated the activation and differentiation of naive T cells (O’Connell et al., 2006; Sacramento et al., 2018).

### The Regulatory Effect of Neurotransmitters on Immune Cells Infiltrated in the Pancreatic TME

Neuro-immune interactions rely on soluble signaling molecules between cells, which including cytokines, chemokines, neurotransmitters, and neurotrophins. Neurotransmitters can regulate both the local and systemic immune responses against cancers. There is a comprehensive neuro-immune regulatory network existing in the TME, and the communication between neurotransmitters and immune cells influences the fate of cancer with either promoting or inhibiting the cancer growth and metastasis. The well-studied immune mediations caused by neurotransmitters are summarized in Table 3 and Figure 1. Understanding the regulatory effects of various neurotransmitters on cancer immunity can help to design new strategies for cancer therapy.

#### Epinephrine and Norepinephrine

E and NE are mainly secreted by the adrenal medulla and sympathetic nerves, respectively. Local sympathetic innervation provides the bulk of the catecholamine content within the tumor (Zahalka and Frenette, 2020). Excessive activation of sympathetic nerves could damage the anti-tumor immune response, increase the invasion ability of tumor cells, and accelerate the occurrence and development of tumors (Nissen et al., 2018).

E and NE mainly exert immunosuppressive effects. The receptor β-ARs is present in most immune cells such as T cells (including Treg), B cells, macrophages, NK and DC cells (Sarkar et al., 2013). E and NE can inhibit the activity of CD8$^+$ T and NK cells via inducing the apoptosis of these lymphocytes (Zhao et al., 2014). They are known to directly suppress the production of cytokines and T cell proliferation, and potently inhibit TCR-mediated integrin activation on human antigen-specific CD8$^+$ T cells (Leone et al., 2015; Dimitrov et al., 2019). β-AR signal suppressed the production of IL-2 and IFN-γ and proliferation of CD4$^+$ T cells depending on their stage of differentiation (Muthu et al., 2007). The combined application of endogenous E and prostaglandin could reduce the anti-tumor activity of NK cells, thereby promoting the progression of leukemia (Inbar et al., 2011; Meron et al., 2013). Besides, several studies have demonstrated that chronic adrenergic signaling suppresses NK cell activity in solid tumors (Melamed et al., 2005; Tarr et al., 2012; Graff et al., 2018). In addition, β-AR-mediated hormonal signaling could reduce the deformability of macrophages, resulting in the acceleration of tumor metastasis (Kim et al., 2019). NE and E contribute to the macrophage polarization, recruitment, and cytokine production like IL-6 and TNF-α (Izeboud et al., 1999; Chiarella et al., 2014). Activation of β-AR signal could increase the infiltration of macrophages in the primary tumor parenchyma and induce the M2 polarization of macrophages (Dimitrov et al., 2019), which subsequently promoted tumor metastasis and
| Neurotransmitters          | Immune cells       | Effect                                                                 | References                                   |
|----------------------------|--------------------|----------------------------------------------------------------------|----------------------------------------------|
| Epinephrine, norepinephrine| T-lymphocytes      | Inhibit the activity of CD8^+ T cells                                 | Inbar et al., 2011; Dimitrov et al., 2019; Kim et al., 2019 |
|                            | NK cells           | Inhibit the activity of NK cells                                      |                                              |
|                            | Macrophages        | Activation of β-AR signal could increase the infiltration of macrophages in the primary tumor parenchyma and induce the M2 polarization of macrophage, which subsequently promoted tumor metastasis |                                              |
| Serotonin                  | T-lymphocytes      | Releases IL-2, 16 and IFN-γ, T-cell proliferation                      | Uyttenhove et al., 2003; Yin et al., 2006; Mikulski et al., 2010; Inoue et al., 2011 |
|                            | Dendritic cells    | Increasing the Ca^{2+} concentration in immature cells               |                                              |
|                            | Macrophages        | Down-regulating chemokine CCR5 expression and up-regulating chemokine CCL2 and MIP1α expressions. Activating 5-HT2 increases the production and release of M2 cytokines. Inhibits release of TNF-α, inhibits NK cell suppression. |                                              |
|                            | Neutrophils        | Inhibits tumor cell phagocytosis and oxidative burst                  |                                              |
| Dopamine                   | T-lymphocytes      | T cells express functional dopamine receptors (DR) D1R-D5R, but their level and function are dynamic and context-sensitive; DA affects Th1/Th2/Th17 differentiation; D2 activation induces T cells to secrete IL-10; D3 activation promotes T cells to secrete TNF-α, IFN-γ; D5 activation promotes T cells to secrete TNF-α and IL-10 Activation of D1 and D4 up-regulate the activity of cAMP and transcription factors STAT5 and GATA3, and promote the differentiation of T cells to TH2; DA inhibits the suppressive activity of Treg DA activates resting effector T cells (Teffs) resulting in their proliferation and cytokine production. T cells produce DA (Tregs >> Teffs), release DA, mainly after mitogen/antigen/CD3 ± CD28/PKC activation, uptake extracellular dopamine, and need DA. DA is important for antigen-specific interactions between T cells and dendritic cells. | Sarkar et al., 2006, 2013; Lèveque, 2016; Talhada et al., 2018 |
|                            | Dendritic cells    | Activating the D1 receptor on DC promotes ERK/JNK/NF-κB signaling, and inducing cytokine production |                                              |
|                            | B-lymphocytes      | Activating the D1 receptor on B cells increases the expression of its inducible ICOSL and CD40L. |                                              |
| GABA                       | T-lymphocytes      | Suppressing the immune effect by inhibiting the activation of NF-κB.   | Bergeret et al., 1998; Prud’homme et al., 2015 |
|                            | Macrophages        | Inhibiting the activation of macrophages by blocking calcium signals. Up-regulating the expression of the chemokines CXCL5 and CCL20. |                                              |
| Substance P                | T-lymphocytes      | Affecting the activity and migration ability of CD8^+ T cells         | Mashaghi et al., 2016; Shahnazad et al., 2018 |
|                            | Dendritic cells    | Regulating the movement of dendritic cells toward lymph nodes via modulating the expression of chemokine receptors and adhesion molecules. |                                              |
|                            | Macrophages        | Activating NF-κB signaling in macrophages increases the production of pro-inflammatory cytokines, and therefore amplified the inflammatory response mediated by Th1 or Th17 |                                              |
|                            | Peripheral blood monocytes | Producing pro-inflammatory cytokines, such as IL-1, IL-6, IL-12 and TNF-α |                                              |
|                            | Neutrophils        | Participating in migration of neutrophils                            |                                              |
| NPY                        | T-lymphocytes      | Promoting the polarization of Th2 polarizing by upregulating the production of IL-6 and IL-10 | Wheway et al., 2007a,b |
|                            | Dendritic cells    | Inducing migration of immature DCs through the engagement of NPY Y1 receptor and the activation of ERK and p38, and exerting proinflammatory effects through the recruitment of immature DCs |                                              |
| CGRP                       | Dendritic cells    | Inhibiting the capacity of dendritic cells to produce inflammatory cytokines and to present antigens to T cells | Fox et al., 1997; Holzmann, 2013 |
|                            | Macrophages        | Inhibition macrophages and upregulation of IL-10, IL-10-independent induction of the inducible cAMP early repressor (ICER) and inhibition of NF-κB activity |                                              |
FIGURE 1 | The role of neurotransmitters and the emergence of nerves in the pancreatic tumor microenvironment (TME). Tumor innervation is present as shown by the extension of nerve fibers into the solid tumor, while perineural invasion (PNI) is present as shown by the invasion of cancer cells into the perineurium of the nerve (Left panel). The outgrowth of nerves in TME (axonogenesis) is partly driven by the secretion of neurotransmitters released by sympathetic nerves and other tissues or cells. In return, nerve fibers as branches of neuron infiltrate the TME, could regulate tumor growth and metastasis. Schematic representation of different neurotransmitters, their respective receptors, target cells as well as pro/antitumor activity of specific neurotransmitter/receptor axis (Right panel). Neurotransmitters are an active component of the TME. Neurotransmitters released by neuro-endocrine-immune system and other tissues or cells can promote cancer cell proliferation, migration, and invasion through the stimulation of specific membrane receptors. Moreover, immune cells infiltrated in the TME likewise express diverse neurotransmitter receptors and react with neurotransmitter, are known to have a strong impact on tumor angiogenesis and inflammation. PNI, perineural invasion; TME, tumor microenvironment; MDSC, myeloid-derived suppressor cells. The figure was created with BioRender.com.

stimulated tumor cells to produce chemokines like M-CSF (Van Overmeire et al., 2016). The use of β-blocker propranolol reduced the immunosuppression function of MDSC in breast cancer and enhances the effect of other cancer therapies like anti-PD-1 treatment and irradiation (Mohammadpour et al., 2019).

In pancreatic TME, it was shown that NE and E could decrease the expressions of MHC-I molecules and the costimulatory ligand B7-1 in PC cells, and increase the expressions of immunosuppressive IDO, PD-1, and PD-L1 (Arreola et al., 2015). Although these changes only last for a short time, these phenotypic changes of cancer cells do not only prevent the antigen recognition by T cells, but also damage T cell function by depleting essential nutrients, such as tryptophan, and inducing the exhaustion of activated lymphocytes (Zhao et al., 2014). β-adrenergic activation directly inhibits the generation of CTL and blocks the recruitment of protective T cells in the tumor microenvironment (Nakai et al., 2014). In PC, stress-induced neural activation is related to increased primary tumor growth and tumor cell dissemination to the normal adjacent pancreas. These effects were associated with increased expression of invasion genes by tumor cells and pancreatic stromal cells in the microenvironment (Kim-Fuchs et al., 2014). Enriching the housing environment for mice could enhance the cytotoxic activity of NK cells and promote tumor-infiltrating NK cells via sympathetic nerve-dependent mechanisms. Application of the β-blocker largely abolished the effects of the enriched environment on NK cells and attenuated its anti-tumor function (Song et al., 2017).

Taken together, adrenergic signaling mainly exhibits pro-tumorigenic properties. This effect is generated in part through the enhanced immune evasion induced by E and NE. The inhibition of adrenergic signaling increases the antitumor immune response via its impact on multiple immune cells, supporting the potential value of adrenergic antagonists in cancer prevention and treatment.

Serotonin
In the brain, 5-HT is synthesized by neurons located in the raphe nucleus of the brainstem (Migliarini et al., 2013). Externally, less than 1% of free 5-HT exists in the blood, and the rest is stored in platelets, presynaptic neurons, and intestinal enterochromaffin cells (Kim et al., 2019). 5-HT is a multifunctional molecule that regulates immune function (Arreola et al., 2015). It is now known...
that there are seven different 5-HT receptor subtypes: 5-HT1 to 5-HT7. Except 5-HT3, which is a ligand-gated ion channel, all the other 5-HT receptors belong to the G protein coupled receptor family. Most immune cells express 5-HT receptors. 5-HT1 is mainly expressed in innate immune cells such as the mast cells (Kushnir-Sukhov et al., 2006), macrophages (Nakamura et al., 2008), DCs (Durk et al., 2005), and monocytes (Soga et al., 2007); 5HT-2 is expressed in eosinophils and macrophages (Mikulski et al., 2010). In the adaptive immune system, proliferated T cells mainly express 5-HT1B, 5-HT2A, and 5-HT7, and B cells mainly express 5-HT1A and 5-HT3 (Yin et al., 2006; Inoue et al., 2011).

5-HT is a neuromodulator with neurotransmitter and neuroendocrine functions in cancer (Balakrishna et al., 2021). Meanwhile, it also regulates a variety of immune processes, such as immune cell chemotaxis, activation, proliferation, and cytokine secretion (Herr et al., 2017). SERT blockers including the serotonin selective reuptake inhibitors (SSRI) which increase extracellular 5-HT concentration have immunoinhibitory effects (Gobin et al., 2014). In T cells, 5-HT induces T cell differentiation into Treg cells and promotes the shift of Th17 cells to Tregs. 5-HT acts on Th17 to induce the secretion of IFN-γ and IL-17 and elevates the release of IL-10 from Tregs, which indirectly promote the development of tumors (Sacramento et al., 2018). In DC cells, 5-HT elevates the Ca²⁺ concentration in immature cells, and contributes to the differentiation and maturation of DCs by activating 5-HT4 and 5-HT7. This activation could up-regulate cAMP levels in DCs (Carhart-Harris and Nutt, 2017) and the secretion of related cytokines such as IL-1β, IL-6, IL-8, and IL-10 (Idzko et al., 2004; Katoh et al., 2006). In macrophages, 5-HT regulates the polarization of macrophages through both activated and inhibitory signals. 5-HT2A activation increases the production of M2-type cytokines and migration while 5-HT1A activation enhances the capability of phagocytosis in macrophages (Mikulski et al., 2010; de las Casas-Engel et al., 2013). Activation of 5-HT1A on lung cancer cells could induce immune evasion via autophagy. After the activation, the ratio of TH1/TH2 cells decreased and the number of Tregs increased in TME, which suggesting a resistance to CTL attack (Liu et al., 2019).

In the pancreas, 5-HT is profoundly implicated in acute pancreatitis, pancreas regeneration after pancreatitis and PC. In the pancreatic TME, the SSRI fluoxetine reduced the stromal reaction that surrounds pancreatic lesions, evidenced by decreased fibrosis, inflammation and angiogenesis (Saponara et al., 2018). The intratumoral MAOA expression was also associated with T cell dysfunction and decreased patient survival in a broad range of cancer patients including PC (Wang et al., 2021).

In summary, in most cases, serotonin signaling influences immune cells and facilitates tumor development via suppression of anti-tumor immunity. Therefore, the use of anti-anxiety or anti-depressant drugs targeting serotonergic system may have potential implications in cancer therapy.

**Dopamine**

Dopamine contributes to neuroimmune communication and acts on immune cells in an autocrine/paracrine manner through its receptors (Roy et al., 2000). Dopamine receptors are functionally classified into the D1-like subtypes consisting of D1R and D5R and D2-like subtypes (D2R, D3R, and D4R receptors), based on their ability to stimulate the formation or inhibition of cAMP (Kebabian, 1978).

Dopamine mainly acts on T cells and trigger DA receptor-dependent activation of ERK, LCK, FYN, and NF-κB pathways (Ghosh et al., 2003). In T cells, the activation of D2R and D5R can induce IL-10 (Besser et al., 2005; Cosentino et al., 2007), while D3R activation induces TNF-α and IFN-γ secretion (Ilani et al., 2004). Besides, the stimulation of D3R in naive CD8⁺ T cells also contributed to the regulation of chemotaxis and related cellular function like extravasation and adhesion (Huang et al., 2010; Figureoa et al., 2017). DA affects Th1/Th2/Th17 differentiation. Specifically, the activation of D1R and D4R enhanced the TH2 differentiation by up-regulating the activity of cAMP, STAT5, and GATA3. Besides, DA mediated the chemotactic migration of naive CD8⁺ T cells by inducing chemokines like CCL19, CCL21, and CXCL12 (Watanabe et al., 2006). It was reported that DA inhibits the proliferation of T cell and the secretion of IL-2, IL-6, and IFN-γ when exposed to a high level of DA (Bergquist et al., 1997; Saha et al., 2001). DA could activate D1-like receptors in Treg, which in turn indirectly activates effect T cell (Cosentino et al., 2007). Except for T cells, inhibition of the DR3-mediated signal in DC cells increased the cross-presentation of antigen to CD8⁺ T cells (Figureoa et al., 2017).

Dopamine functions as a regulatory component on immune cells in the TME (Yan et al., 2015; Petrelli, 2017). Increased level of plasma DA (40–80 pg/ml) was reported to evidently impair physiological proliferation and cytotoxicity of T cells in cancer patients (Saha et al., 2001). In PC, DA enhanced the chemotherapeutic efficacy of gemcitabine both in vitro and in immunocompetent murine models, and changed TME by suppressing the M2 characters of TAMs. Specifically, the activation of D4R in macrophages by DA reduced the production of cAMP, and then inhibited the activation of PKA/p38 signal pathway, which suppressed the transcription of tumor-promoting cytokines of TAMs such as IL-1β and TNF-α (Liu Q. et al., 2021). What’s more, DA was found to hinder the function of tumor-induced monocyctic MDSCs on the proliferation and IFN-γ production of T cells in lung and melanoma cancer (Hoepner et al., 2015; Wu J. et al., 2015). DA attenuated NO production by MDSCs directly, mediated by decreased iNOS expression and the downregulation of ERK and JNK signaling pathways. DA-induced activation of resting Tefs and suppression of Tregs seem beneficial for the immunotherapy of cancer. As for the receptors, D2R was identified as an upregulated protein in PC, and D2R antagonists (pimozone and haloperidol) reduced PC growth and particularly metastasis (Jandaghi et al., 2016). The anti-tumor efficacy of ONC201 and ONC212, two small molecule antagonists of D2R, were observed in vivo either administrated as a single agent or in combination with 5-fluorouracil, irinotecan, and oxaliplatin. When treated with ONC201, a broad induction of immune cytokines and effector molecules was observed among PC patients with longer progression-free survival (Lev et al., 2017; Stein et al., 2019). Besides, ONC201 has been reported to induce the proliferation of...
NK cells and activation via TRAIL and granzyme B in preclinical studies (Stein et al., 2019).

Together, the current findings suggest an important immunomodulatory effect of DA in cancer microenvironment. DA may confer immunopromoting or immunosuppressive effect dependent on the types of immune cells and the specific DA receptor they express.

**Gamma-Aminobutyric Acid**

Gamma-aminobutyric acid is the main inhibitory neurotransmitter in the central nervous system. In the periphery, GABA is produced by pancreatic β cells, T cells, and macrophages. These cells also express other components of the GABAergic system, including receptors, transporters, and metabolic enzymes (Wu et al., 2017). The GABAergic signaling system affects various functional characteristics of immune cells, such as antigen-induced T cell proliferation (Bjurstom et al., 2008) and LPS-induced cytokine release and effector T cell activity (Lang et al., 2003).

Both in vivo and in vitro studies have proved that GABA suppresses the immune effect by inhibiting the activation of NF-kB and reducing the production of inflammatory cytokines (Bhat et al., 2010). As a negative regulator in the TME, GABA inhibits the activation of macrophages and T cells by blocking calcium signals and inhibiting NF-kB pathway (Prud'homme et al., 2015). In addition, GABA was shown to regulate the expression of GABA-A receptor subunits on immune cells (Bergeret et al., 1998; Feske et al., 2012). In the pancreatic TME, GABRP expression was remarkably increased in PC tissues among other neurotransmitters' receptors. GABRP expression correlated with macrophages density closely, and the deletion of macrophages largely abrogated the oncogenic functions of GABRP in PC. The GABRP on cancer cells promoted macrophages recruitment by inducing CXCL5 and CCL20 expression. Specifically, GABRP might act as a chaperone protein and regulate the activity of KCNN4 channel to induce Ca$^{2+}$ signaling in PC cells. The GABRP-KCNN4 complex led to the activation of NF-kB, which further facilitated CXCL5 and CCL20 transcription to induce macrophage infiltration in PC (Jiang et al., 2019).

In general, GABA exerts immunosuppressive effects on diverse immune cells and blockade of GABA signaling in the microenvironment may improve the anti-tumor immune response against cancer cells.

**Neuropeptides**

Most studies related to the immunomodulatory effect of neuropeptides focused on the substance P. In the central system, substance P is released from the brain regions and regulates emotions and specific sensory nerve endings (Cunin et al., 2011; Munoz and Covenas, 2015). In the periphery, substance P is mainly secreted by immune cells such as macrophages and DC cells (Janelins et al., 2013). Substance P exerts its biological activity through G protein-coupled neurokinin receptors (NKR)s, namely NK-1R, NK-2R, and NK-3R (Suvas, 2017). NK-1R mainly exists in the immune system and mediates the effect of substance P on immune cells (Shahzad et al., 2018). Substance P acts on NK-1R to induce a local inflammatory environment in a concentration-dependent manner. Specifically, substance P mediates the migration, proliferation, and activation of immune cells. Substance P activated NF-kB signaling in macrophages, increased the production of pro-inflammatory cytokines such as CCL2, CXCL2, and IL-8 (Levite, 2008). Therefore substance P amplified the inflammatory response mediated by TH1 or TH17 (Cunin et al., 2011; Mashaghi et al., 2016). Recent studies illustrated that administration of substance P during the primary immune response amplifies the secondary immune response by activating CD8$^+$ T cells (Ikeda et al., 2007). Substance P increased the migration of immune cells, including T cells and neutrophils, through a β-arrestin-dependent mechanism (Nichols et al., 2012). Substance P also stimulated human PBMC to produce pro-inflammatory cytokines including IL-1, IL-6, IL-12, and TNF-α (Cunin et al., 2011). As for innate immune cells, substance P activated NK cells and neutrophils by up-regulating their production of cytotoxic-associated molecules, such as perforin and granzyme (Fu et al., 2011; Mashaghi et al., 2016). However, the up-regulation of the NK-1R can be seen in both chronic pancreatitis and PC and enhanced NK-1R expressions were related to advanced tumor stage and a poorer prognosis (Li et al., 2013). In addition, CD10$^+$ fibroblasts can inhibit squamous cancer cells invasion ability by diminishing substance P (Xie et al., 2010).

The peripheral sensory nerves, which mediate pain reflexes, may influence immune responses through the release of neuropeptides CGRP (Holzmann, 2013). CGRP directly acts on macrophages and dendritic cells and inhibits the capacity of these cells to produce inflammatory cytokines and to present antigens to T cells. The molecular mechanisms, by which CGRP acts on innate immune cells, include the upregulation of IL-10, IL-10-independent induction of the inducible cAMP early repressor (ICER) and inhibition of NF-kB activity (Fox et al., 1997). In addition, Liu et al. demonstrated that increased CGRP and neuronal p75 immune-reactivities in tumor-bearing mice, promoting chronic pain in bone metastasis (Liu et al., 2020).

Neuropeptide Y was found to induce a dose-dependent migration of immature DCs through the engagement of NPY Y1 receptor and the activation of ERK and p38. Meanwhile, NPY promoted the polarization of TH2 polarizing by upregulating the production of IL-6 and IL-10 (Wheway et al., 2007a,b). Thus, NPY may exert proinflammatory effects through the recruitment of immature DCs, but it may exert anti-inflammatory effects by promoting a TH2 polarization. In prostate cancer, depression-induced NPY secretion might promote the tumor infiltration of myeloid cells and therefore contribute to cancer progression (Cheng et al., 2019).

Taken together, the neuropeptides CGRP and NPY were suggested to impair the anti-tumor immunity and their inhibition may be a potential strategy for cancer treatment. On the contrary, substance P may facilitate the anti-tumor immune response. However, enhancing the substance P signaling in cancer cells could promote the progression of pancreatic cancer. The distinction between signaling mechanisms of...
substance P in immune cells and cancer cells warrants further studies.

**NEUROTRANSMITTER-TARGETED DRUGS AS COMBINATORIAL STRATEGIES FOR CANCER IMMUNOTHERAPY**

The important role of neurotransmitters in cancer progression suggests that the drugs targeting neurotransmitter signaling may act as promising candidates for cancer treatment (Cole et al., 2015). In fact, the clinical trials of various neurotransmitter receptor antagonists or agonists are already ongoing (Table 4). Among them, β-blockers, which are the antagonists targeting adrenergic β receptors, are mostly studied (Rotteri et al., 2013; Grytli et al., 2013a,b). Data from prostate cancer and breast cancer studies showed that patients using β-blockers, even former users, had significantly better survival outcomes than the non-users (Grytli et al., 2013b; De Giorgi et al., 2018). In melanoma, pan β-blockers provided more survival benefits than β1- or β2-selective blockers (Livingstone et al., 2013). In PC, long-term use of beta-blockers especially selective β1-blockers may be associated with decreased cancer risk (Saad et al., 2020). Besides, β-blocker drugs may lead to a significantly improved overall prognosis in PC patients, particularly among those with localized disease (Saad et al., 2020). These findings raise the possibility that neurotransmitters-related drugs protect from cancer initiation.

Recently, immunotherapy is emerging as the most promising treatment option for cancers. However, immunosuppressive mechanisms within the TME largely limit its therapeutic efficacy. As aforementioned, neurotransmitters not only have direct effects on tumor cells, but also contribute to the immunosuppressive microenvironment by acting on immune cells in the TME. Therefore, neurotransmitter-targeted drugs have attracted increasing attentions as a combinatorial approach for cancer immunotherapy. In murine tumor models, reducing β-AR signaling was shown to facilitate the conversion of TME to an immunologically active microenvironment, and β-blockers application significantly increased the efficacy of anti-PD-1 checkpoint blockade (De Giorgi et al., 2018). In addition, blocking β-AR signaling also improved the potency

---

**TABLE 4 | Clinical trials related to neurotransmitters in cancer.**

| Related neurotransmitter | Cancer type and stage | Purpose | Strategy or treatment | Enrolled patients | Therapeutic effects | References |
|--------------------------|-----------------------|---------|-----------------------|------------------|-------------------|------------|
| Catecholamine (E/NE)     | Head and neck. Stomach. Colon. Prostate cancer. | Investigate the association between propranolol and cancer | Patients with a usage of propranolol >6 months in NHIRD database | 24,238 | HR:0.58 (95%CI: 0.35–0.95) HR:0.55 (95%CI: 0.31–0.97) | Chang et al., 2015 |
| Catecholamine (E/NE)     | Locally advanced and metastatic melanoma | Investigate the efficacy of combination with propranolol and pembrolizumab | Propranolol twice a day with pembrolizumab 200 mg every 3 weeks | 9 | In progress (ORR = 78%) | Gandhi et al., 2021 |
| Serotonin                | Breast cancer with obesity or/and overweight | Exam the effects of Mediterranean Diet and Naltrexone/Bupropion Treatment in Obese Breast Cancer Patients | Naltrexone/bupropion combination (NB)β release (ER) combination tablets, Mediterranean Diet | 72 | The combination of the Mediterranean diet with naltrexone/bupropion treatment | NCT03581630 (Cho et al., 2020) |
| Dopamine Pituitary adenoma; Non-functioning pituitary adenoma | Investigate the efficacy of cabergoline in NFPA individuals with remaining tumor after primary neurosurgery | Cabergoline (a DRD2 antagonist and antiparkinson drug) | 140 | Residual tumor shrinkage: 10.5% vs. 28.8%, stabilization = 66.1% vs. 73.7%, enlargement = 5.1% vs. 15.8% (the control group) PFS: 23.2M vs. 20.8M (the control group) | NCT03271918 (Batista et al., 2019) |
| Dopamine Recurrent and stage IV breast cancer | Investigate the effectiveness of cabergoline in treating metastatic breast cancer disease in those who test positive for the prolactin receptor | Cabergoline (a DRD2 antagonist and antiparkinson drug) | 20 | CBR = 33% (6/18), mPFS = 1.9M, mOS = 10.4M | NCT01730729 (Costa et al., 2017) |
| Dopamine Advanced solid cancer refractory to the standard treatment | Evaluate the safety and pharmacokinetics of weekly ONC201 | ONC201 (a DRD2 antagonist) | 20 | Enhance immunostimulatory activity | NCT02250781 (Stein et al., 2019) |
of TCR-γ T-cell therapeutics in hematologic malignancies (Baker et al., 2019) and enhanced the antitumor efficacy of STxB7-based cancer vaccine in a breast cancer model (Daher et al., 2019). Small-molecule MAO inhibitors (MAOIs), used for depression and other neurological disorders, was found to significantly suppress tumor growth and generated synergistic tumor suppression effects when combined with anti-PD-1 treatment. Specifically, MAO-A restraints antitumor T cell immunity through controlling intratumoral T cell autocrine serotonin signaling. Apart from β-blockers and MAOIs (Wang et al., 2021), the results from preclinical studies provide a rationale for testing this combinatorial strategy in cancer patients.

The first prospective study on the combination of immunotherapy and a neurotransmitter receptor antagonist drug was conducted in melanoma patients (De Giorgi et al., 2018; Gandhi et al., 2021). It was shown that the patients taking propranolol, an approved non-selective β-blocker, not only had an 80% risk reduction for recurrence but also tended to be more sensitive to anti-PD-1 treatment (De Giorgi et al., 2018). The enhanced therapeutic efficacy of immune checkpoint inhibitors by β-blocker was also observed in lung cancer patients. The use of β-blockers was significantly associated with improved progression-free survival among non-small-cell lung cancer patients treated with SP-142, a PD-L1 inhibitor (Oh et al., 2021).

Pancreatic cancer is among the most immune-resistant tumor types. Given the potential role of neurotransmitters in the immunosuppressive microenvironment of PC, drugs targeting neurotransmitter signaling may help to limit immune suppression and overcome immunotherapy resistance in PC. The combination of neurotransmitter signaling-targeted drugs and immunotherapy is believed to provide new hope for PC patients (Balachandran et al., 2019).

CONCLUSION

Pancreatic cancer has the unique characteristic of increased neural density. As the messenger molecules, neurotransmitters have emerged as components with significant importance in the TME of pancreatic cancer. Neurotransmitters can directly bind to the cancer cells, generating either promoting or inhibition effects on cancer growth. Meanwhile, the expressions of neurotransmitters and their corresponding receptors in the tumor-infiltrating immune cells imply a complicated relationship between the neurotransmitters and the immune cells in the TME. Further investigation on how neurotransmitters crosstalk with immune cells at the TME level will be of great interest, for it will facilitate our understanding of the mechanism behind the suppressive immune microenvironment of cancer. The tumor immune microenvironment contributes a lot to the initiation and development of cancers, as well as the response to cancer treatments, notably the immunotherapy. Nowadays, immunotherapy is increasingly involved in cancer therapeutic regimes. Breaking immune tolerance using specific receptor antagonists of neurotransmitters is possibly a promising strategy for combinatorial therapy with immune checkpoint inhibitors in PC. It is also plausible that modulating the expression of neurotransmitter receptors on the surface of CAR-T cells may promote the efficacy of CAR-T therapy. Further research into the precise mechanism of how immune cells regulated by different types of neurotransmitters in the TME might open up new avenues toward adjunct therapy against PC.

AUTHOR CONTRIBUTIONS

YL wrote the manuscript. HL searched the literatures, made the tables, and polished the language. HT and YG conceived the idea and revised the manuscript. All authors read and approved the final manuscript.

FUNDING

This study was supported by the grants from the National Natural Science Foundation of China (81872505, 82073406, and 81572312).
Entschladen, F., Palm, D., Niggemann, B., and Zaenker, K. S. (2008). The cancer's nervous tooth: considering the neuronal crosstalk within tumors. Semin. Cancer Biol. 18, 171–175. doi: 10.1016/j.semcancer.2007.12.004

Feske, S., Skonlik, E. Y., and Prakriya, M. (2012). Ion channels and transporters in lymphocyte function and immunity. Nat. Rev. Immunol. 12, 532–547. doi: 10.1038/nri3323

Figuerola, C., Galvez-Cancino, F., Oyarce, C., Contreras, F., Prado, C., Valeria, C., et al. (2017). Inhibition of dopamine receptor D3 signaling in dendritic cells increases antigen cross-presentation to CD8(+) T-cells favoring anti-tumor immunity. J. Neuroimmunol. 303, 99–107. doi: 10.1016/j.jneuroim.2016.12.014

Fox, F. E., Kubin, M., Cassin, M., Niu, Z., Hosoi, J., Torii, H., et al. (1997). Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12. J. Invest. Dermatol. 108, 43–48. doi: 10.1111/j.1523-1747. ep12285627

Francis, T., Graf, A., Hodges, K., Kennedy, L., Hargrove, L., Price, M., et al. (2013). Histamine regulation of pancreatitis and pancreatic cancer: a review of recent findings. Hepatobiliary Surg. Nutr. 2, 216–226. doi: 10.3978/j.issn.2304-3881.2013.08.06

Fu, W. X., Qin, B., Zhou, A. P., Yu, Q. Y., Huang, Q. J., and Liang, Z. F. (2011). Regulation of NK92-MI cell cytotoxicity by substance P. Scand. J. Immunol. 74, 107–113. doi: 10.1111/j.1365-3083.2011.02550.x

Gandhi, S., Pandey, M. R., Attwood, K., Ji, W., Witkiewicz, A. K., Knudsen, E. S., et al. (2021). Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor activity. Clin. Cancer Res. 27, 87–95. doi: 10.1158/0885-0741.CCR-20-2381

Ghos, M. C., Mondal, A. C., Basu, S., Banerjee, S., Majumder, J., Bhattacharya, G., et al. (2003). Dopamine inhibits cytokine expression and release of tryptophan kinases, Lck and Fyn in activated T cells. Int. Immunopharmacol. 3, 1019–1026. doi: 10.1016/S1387-3135(03)00100-0

Gobin, V., Van Steendam, K., Denys, D., and Deforce, D. (2014). Selective serotonin reuptake inhibitors as a novel class of immunosuppressants. Int. Immunopharmacol. 20, 148–156. doi: 10.1016/j.intimp.2014.02.030

Gottschke, C. R., and Woldbye, D. P. (2016). Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells. Mol. Oncol. 9, 270–281. doi: 10.1016/j.molonc.2014.08.008

Holzmann, B. (2013). Antiinflammatory activities of CGRP modulating innate immune responses in health and disease. Curr. Protein Pept. Sci. 14, 268–274. doi: 10.2174/138920371149990046

Homerndorff, H., and Jobling, P. (2018). The sympathetic nervous system drives tumour angiogenesis. Trends Cancer 4, 93–94. doi: 10.1016/j.trecan.2017.11.008

Hosein, A. N., Brekken, R. A., and Maitra, A. (2020). Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat. Rev. Gastroenterol. Hepatol. 17, 487–505. doi: 10.1038/s41575-020-0300-1

Huang, C., Li, Y., Guo, Y., Zhang, Z., Lian, G., Chen, Y., et al. (2018). MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells. Theranostics 8, 3074–3086. doi: 10.7150/thno.24281

Huang, X. Y., Wang, H. C., Yuan, Z., Huang, J., and Zheng, Q. (2012). Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via beta-adrenergic receptor-dependent activation of P38/MAPK pathway. Hepatogastroenterology 59, 889–893. doi: 10.5774/hiage11476

Huang, Y., Qiu, A. W., Peng, Y. P., Liu, Y., Huang, H. W., and Qiu, Y. H. (2010). Roles of dopamine receptor subtypes in mediating modulation of T lymphocyte function. Neuro Endocrinol. Lett. 31, 782–791.

Hujber, Z., Horvath, G., Petovari, G., Krencz, I., Danko, T., Meszaros, K., et al. (2013a). Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells. Mol. Oncol. 9, 270–281. doi: 10.1016/j.molonc.2014.08.008

Idzko, M., Panther, E., Stratz, C., Muller, T., Bayer, H., Zissel, G., et al. (2004). The role of dopamine receptor subtypes in mediating modulation of T lymphocyte function. Neuro Endocrinol. Lett. 31, 782–791.

Ilani, T., Streus, R. D., and Fuchs, S. (2004). Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells. FASEB J. 18, 1600–1602. doi: 10.1096/fj.04-4652f6

Inbar, S., Neeman, E., Avraham, R., Benish, M., Rosenne, E., and Ben-Eliyah, S. (2011). Do stress responses promote leukemia progression? An animal study suggesting a role for epinephrine and prostaglandin-E2 through reduced NK activity. PLoS One 6:e19246. doi: 10.1371/journal.pone.0019246

Inoue, M., Okazaki, T., Kitazono, T., Mizushima, M., Oomata, M., and Ozaki, S. (2011). Regulation of antigen-specific CTL and Th1 cell activation through 5-Hydroxytryptamine 2A receptor. Int. Immunopharmacol. 11, 67–73. doi: 10.1016/j.intimp.2010.01.007

Iovino, M., Messana, T., De Pergola, G., Iovino, E., Guastamacchia, E., Giagulli, V. A., et al. (2019). Vigilance states: central neural pathways, neurotransmitters and neurohormones. Endocr. Metab. Immune Disord. Drug Targets 19, 26–37. doi: 10.2174/187153031866610816115720
Neurotransmitters in TME of PC

Izbekoud, C. A., Mocking, J. A., Monshouwer, M., van Miert, A. S., and Witkamp, R. F. (1999). Participation of beta-adrenergic receptors on macrophages in modulation of LPS-induced cytokine release. J. Recept. Signal Transduct. Res. 19, 191–202. doi: 10.1016/S1079-9989(99)036645

Jandaghi, P., Najafabadi, H. S., Bauer, A. S., Papadakis, A. L., Fassan, M., Hall, A., et al. (2016). Expression of DRD2 is increased in human pancreatic ductal adenocarcinoma and inhibitors slow tumor growth in mice. Gastroenterology 153, 1218–1231. doi: 10.1016/j.gastro.2016.08.040

Janelins, B. M., Sutpm, T. L., Tkacheva, O. A., Rojas-Canales, D. M., Erdos, G., Mathers, A. R., et al. (2013). Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. Blood 121, 2923–2933. doi: 10.1182/blood-2012-07-446054

Jiang, S. H., Li, J., Dong, F. Y., Yang, J. Y., Liu, D. J., Yang, X. M., et al. (2017). Increased serotonin signaling contributes to the warburg effect in pancreatic tumor cells under metabolic stress and promotes growth of pancreatic tumors in mice. Gastroenterology 153, 277–291.e19. doi: 10.1016/j.gastro.2017.03.008

Jiang, S. H., Zhu, L. L., Zhang, M., Li, R. K., Yang, Q., Yan, J. Y., et al. (2019). GABBR regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca(2+) signalling in a GABA-independent manner. Gut 68, 1994–2006. doi: 10.1136/gutjnl-2018-317479

Jurcak, N., and Zheng, L. (2019). Signaling in the microenvironment of pancreatic cancer: Transmitting along the nerve. Pharmcol. Ther. 200, 126–134. doi: 10.1016/j.pharmthera.2019.04.010

Katoh, N., Soga, F., Nara, T., Tamagawa-Mineoka, R., Nin, M., Kotani, H., et al. (2019). Signaling in the microenvironment of pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget 8, 81776–81793. doi: 10.18632/oncotarget.28019

Levite, M. (2008). Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr. Opin. Pharmacol. 8, 460–471. doi: 10.1016/j.coph.2008.05.001

Levite, M. (2016). Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases. Acta Physiol. (Oxf.) 216, 42–89. doi: 10.1111/apha.12476

Li, X., Ma, G., Ma, Q., Li, W., Liu, J., Han, L., et al. (2013). Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells. Mol. Cancer Res. 11, 294–302. doi: 10.1158/1541-7786.MCR-12-0609

Li, X., Wang, Z., Ma, Q., Xu, Q., Liu, H., Duan, W., et al. (2014). Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. Clin. Cancer Res. 20, 4326–4338. doi: 10.1158/1078-0432.CCR-13-3426

Lifantseva, N. V., Koneeva, T. O., Voronezhskaya, E. E., and Melnikova, V. I. (2017). Expression of components of the serotonergic system in the developing rat thymus. Dokl. Biochem. Biophys. 477, 404–407. doi: 10.1134/S0024320517050082

Lifantseva, N. V., Koneeva, T. O., Voronova, S. N., Zakharova, L. A., and Melnikova, V. I. (2016). The inhibition of dopamine synthesis in fetuses changes the pattern of T-lymphocyte maturation in the thymus of adult rats. Dokl. Biochem. Biophys. 470, 342–344. doi: 10.1134/S1607672916050082

Ligorio, M., Sil, S., Malagon-Lopez, J., Nieman, L. T., Miscale, S., Di Piolo, M., et al. (2019). Stroma microenvironment shapes the intratumoral architecture of pancreatic cancer. Cell 178, 160–175.e7. doi: 10.1016/j.cell.2019.05.012

Li, Y., Xu, J., and Lan, H. (2019). Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J. Hematol. Oncol. 12:76. doi: 10.1186/s13045-019-0760-3

Liou, G. Y., Bastea, L., Fleming, A., Doppler, H., Edenfield, B. H., Dawson, D. W., et al. (2017). The presence of interleukin-13 at pancreatic ADM/PanIN lesions alters macrophage populations and mediates pancreatic tumorigenesis. Cell Rep. 19, 1322–1333. doi: 10.1016/j.celrep.2017.04.052

Liu, C., Goel, P., and Kaeser, P. S. (2021). Spatial and temporal scales of dopamine transmission. Nat. Rev. Neurosci. 22, 345–358. doi: 10.1038/s41583-021-00455-7

Liu, Q., Zhang, R., Zhang, X., Liu, J., Wu, H., Li, Y., et al. (2021). Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations. Cancer Immunol. Immunother. doi: 10.1007/s00262-020-02816-0 [Epub ahead of print].

Liu, Y., Zhang, H., Wang, Z., Wu, P., and Gong, W. (2019). 5-Hydroxytryptamine 1A receptors on tumour cells induce immune evasion in lung adenocarcinoma patients with depression via autophagy/pSTAT3. Eur. J. Cancer 114, 8–24. doi: 10.1016/j.ejca.2019.03.017

Liu, Z., Murphy, S. F., Huang, J., Zhao, L., Hall, C. E., Schaeffer, A. J., et al. (2020). A novel immunocompetent model of metastatic prostate cancer-induced bone pain. Prostate 80, 782–794. doi: 10.1002/pros.23993

Livingstone, E. F., Hollestein, L. M., van Herk-Sukel, M. P., van de Poll-Franse, L., Nijsten, T., Schadendorf, D., et al. (2013). beta-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study. Eur. J. Cancer 49, 3863–3871. doi: 10.1016/j.ejca.2013.07.141

Magnar, C., Hall, S. J., Lin, J., Xue, X., Gerber, L., Freedland, S. J., et al. (2013). Autonomic nerve development contributes to prostate cancer progression. Science 341:1236361. doi: 10.1126/science.1236361

Marino, F., and Cosentino, M. (2013). Adrenergic modulation of immune cells: an update. Amino Acids 45, 55–71. doi: 10.1007/s00726-011-1186-6

Mashaghi, A., Marmalidou, A., Tehrani, M., Grace, P. M., Pothoulakis, C., and Dana, R. (2016). Neuropeptide substance P and the immune response. Cell. Mol. Life Sci. 73, 4249–4264. doi: 10.1007/s00018-016-2293-z

McBurney-Lin, J., Lu, J., Zuo, Y., and Yang, H. (2019). Locus coeruleus- noradrenaline modulation of sensory processing and perception: a focused review. Neurosci. Biobehav. Rev. 105, 190–199. doi: 10.1016/j.neubiorev.2019.06.009

Medeiros, P. J., and Jackson, D. N. (2013). Neuropeptide Y Y5-receptor activation on breast cancer cells acts as a paracrine system that stimulates VEGF expression and secretion to promote angiogenesis. Peptides 48, 106–113. doi: 10.1016/j.peptides.2013.07.029

Melamed, R., Rosenne, E., Shakkar, K., Schwartz, Y., Abudarham, N., and Ben-Eliyahu, S. (2005). Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prolylcarboxypeptidase use.
of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav. Immun. 19, 114–126. doi: 10.1016/j.bbi.2004.07.004

Meron, G., Tisher, Y., Shaashua, L., Rosenne, E., Levi, B., Melamed, R., et al. (2013). PGE2 suppresses NK activity in vivo directly and through adrenal hormones: effects that cannot be reflected by ex vivo assessment of NK cytotoxicity. Brain Behav. Immun. 28, 128–138. doi: 10.1016/j.bbi.2012.11.003

Messlering, K. (2018). The big CGRP flow–sours, sinks and signalling sites in the trigeminovascular system. J. Headache Pain 19:22. doi: 10.1186/s10194-018-0848-0

Migliarini, S., Pacini, G., Pelosi, B., Lunardi, G., and Pasqualetti, M. (2013). Lack of a serotonin precursor in development of gut microvilli. J. Clin. Investig. 129, 5537–5552. doi: 10.1172/JCI29502

Miron, G., Tishler, Y., Shaashua, L., Rosenne, E., Levi, B., Melamed, R., et al. (2013). The impact of beta blockers on survival outcomes in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. Clin. Lung Cancer 22, e57–e62. doi: 10.1016/j.clc.2020.07.016

Orrego, F. (1979). Criteria for the identification of central neurotransmitters, and their application to studies with some nerve tissue preparations in vitro. Neuroscience 4, 1037–1057. doi: 10.1016/0306-4522(79)90186-6

Petrilli, V. (2017). The multifaceted roles of inflammation in cancer. Curr. Opin. Oncol. 29, 35–40. doi: 10.1097/CCO.0000000000000346

Prud’homme, G. J., Glinka, Y., and Wang, Q. (2015). Immunological GABAergic interactions and therapeutic applications in autoimmune diseases. Autoimmun. Rev. 14, 1048–1056. doi: 10.1016/j.autrev.2015.07.011

Puleo, F., Nicolle, R., Blum, Y., Cros, J., Marisa, L., Demetter, P., et al. (2018). Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology 155, 1999–2013.e3. doi: 10.1053/j.gastro.2018.08.033

Qian, R. Z., and Pollard, J. W. (2010). Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39–51. doi: 10.1016/j.cell.2010.03.014

Qian, W., Lv, S., Li, J., Chen, K., Jiang, Z., Cheng, L., et al. (2018). Norepinephrine enhances cell viability and invasion, and inhibits apoptosis of pancreatic cancer cells in a Notch-dependent manner. Oncol. Rep. 40, 3015–3023. doi: 10.3892/or.2018.6696

Reijmen, E., Vannucci, L., De Couck, M., De Greve, J., and Gidron, Y. (2018). Therapeutic potential of the vagus nerve in cancer. Immunol. Lett. 202, 38–43. doi: 10.1016/j.imlet.2018.07.006

Renz, B. W., Takahashi, R., Tanaka, T., Macchini, M., Hayakawa, Y., Dantes, Z., et al. (2018a). beta2 adrenergic-neurotrophin feedforward loop promotes pancreatic cancer. Cancer Cell 34, 863–867. doi: 10.1016/j.ccell.2018.10.010

Renz, B. W., Tanaka, T., Sunagawa, M., Takahashi, R., Liang, Z., Macchini, M., et al. (2018b). Cholinergic signaling via muscarinic receptors directly and indirectly suppresses pancreatic tumorigenesis and cancer stemness. Cancer Discov. 8, 1458–1473. doi: 10.1158/2326-6066.CD-18-0046

Ribeiro, M. P., Custodio, J. B., and Santos, A. E. (2017). Ionotropic glutamate receptor antagonists and cancer therapy: time to think out of the box? Cancer Chemother. Pharmacol. 79, 219–225. doi: 10.1007/s00280-016-1329-0

Riggan, L., Shah, S., and O’Sullivan, T. E. (2021). Arrested development: suppression of NK cell function in the tumor microenvironment. Clin. Transl. Immunol. 10:e2138. doi: 10.1002/cit2.1238

Roggero, E., Besedovsky, H. O., and del Rey, A. (2011). The role of the sympathetic nervous system in the thymus in health and disease. Neuroimmunomodulation 18, 339–349. doi: 10.1159/000329381

Rojghanian, A., Fraser, C., Kleyman, M., and Chen, J. (2016). B cells promote pancreatic tumorigenesis. Cancer Discov. 6, 230–232. doi: 10.1158/2159-8290.CD-16-0100

Roy, R., Singh, S. M., Shanker, A., and Sodhi, A. (2000). Mechanism of thymocyte cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism. Neuroimmunomodulation 9, 23–33. doi: 10.1159/000049004
Saloman, J. I., Albers, K. M., Li, D., Hartman, D. J., Crawford, H. C., Muha, E. A., et al. (2016). Ablation of sensory neurons in a genetic model of pancreatic ductal adenocarcinoma slows initiation and progression of cancer. Proc. Natl. Acad. Sci. U.S.A. 113, 3078–3083. doi: 10.1073/pnas.1512603113

Saponara, E., Visentin, M., Baschieri, F., Seleznik, G., Martinelli, P., Esposito, L., et al. (2018). Serotonin uptake is required for Rac1 activation in Kras-induced acinar-to-ductal metaplasia in the pancreas. J. Pathol. 246, 352–365. doi: 10.1002/path.5147

Sarkar, C., Chakraborty, D., and Basu, S. (2013). Neurotransmitters as regulators of tumor angiogenesis and immunity: the role of catecholamines. J. Neuroimmune Pharmacol. 8, 7–14. doi: 10.1007/s11481-012-9395-7

Sarkar, C., Das, S., Chakraborty, D., Chowdhury, U. R., Basu, D., Dasgupta, P. S., et al. (2006). Cutting edge: stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. J. Immunol. 177, 7525–7529. doi: 10.4049/jimmunol.177.11.7525

Schuller, H. M., Al-Wadei, H. A., Ullah, M. F., and Plummer, H. K. III (2012). beta-adrenergic receptor mediated increases in activation and immune cell signalling in poststroke inflammation. Brain Behav. Immun. 26, 1226–1238. doi: 10.1016/j.bbi.2012.07.002

Thaker, P. H., Han, L. Y., Katam, A. A., Arevalo, J. M., Takahashi, R., Lu, C., et al. (2006). Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 12, 939–944. doi: 10.1038/nm1447

Uyttenhove, C., Pilotte, L., Theate, I., Stroobant, V., Colau, D., Parmentier, N., et al. (2003). Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 9, 1269–1274. doi: 10.1038/nm934

Van Overmeire, E., Stijlenmans, B., Heymann, F., Keirse, J., Morias, Y., Elkrim, Y., et al. (2016). M-CSF and GM-CSF receptor signaling differentially regulate monocyte maturation and macrophage polarization in the tumor microenvironment. Cancer Res. 76, 35–42. doi: 10.1158/0008-5472.CAN-15-0869

Waldmann, J., Fendrich, V., Reichert, M., Hecker, A., Bartsch, D. K., Padberg, W., et al. (2018). Expression of neuropeptide Y and its receptors Y1 and Y2 in pancreatic intraepithelial neoplasia and invasive pancreatic cancer in a transgenic mouse model and human samples of pancreatic cancer. J. Surg. Res. 223, 230–236. doi: 10.1016/j.jss.2017.11.010

Wang, T., Huang, W., and Chen, F. (2008). Baclofen, a GABAB receptor agonist, inhibits human hepatocellular carcinoma cell growth in vitro and in vivo. Life Sci. 82, 536–541. doi: 10.1016/j.lfs.2007.12.014

Wang, X., Li, B., Kim, Y. J., Wang, Y. C., Li, Z., Yu, J., et al. (2021). Targeting monoamine oxidase A for T cell-based cancer immunotherapy. Sci. Immunol. 6:aab8233. doi: 10.1126/sciimmunol.aab8233

Watanabe, Y., Nakayama, T., Nakagubo, D., Hashikawa, K., Jin, Z., Katou, F., et al. (2006). Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3. J. Immunol. 176, 848–856. doi: 10.4049/jimmunol.176.2.848

Wiculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., and Sancho, D. (2020). Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7–24. doi: 10.1038/s41577-019-0210-z

Wheway, J., Herzog, H., and Mackay, F. (2007a). NPY and receptors in immune and inflammatory diseases. Curr. Top. Med. Chem. 7, 1743–1752. doi: 10.2174/156802670772341046

Wheway, J., Herzog, H., and Mackay, F. (2007b). The Y1 receptor for NPY: a key modulator of the adaptive immune system. Peptides 28, 453–458. doi: 10.1016/j.peptides.2006.09.030

Winkler, J., Absiyo-OGunnian, A., Metcalf, K. J., and Werb, Z. (2020). Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11:5120. doi: 10.1038/s41467-020-18794-x

Wouters, M. C. A., and Nelson, B. H. (2018). Prognostic Significance of tumor-infiltrating B cells and plasma cells in human cancer. Clin. Cancer Res. 24, 6125–6135. doi: 10.1158/1078-0452.CCR-17-1481

Wu, C., Qin, X., Du, H., Li, N., Ren, W., and Peng, Y. (2017). The immunological function of GABARP associates with aggressive phenotype of ovarian cancer. Exp. Mol. Med. 49:e335. doi: 10.1038/s41198-017-0032-4

Xie, L., Moroi, Y., Tsuji, G., Liu, M., Hayashida, S., Takahara, M., et al. (2010). Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer cell proliferation and inhibits acinar-to-ductal metaplasia in the pancreas. J. Immunol. 184, 908–917. doi: 10.4049/jimmunol.176.4.176

Yan, Y., Jiang, W., Liu, L., Wang, X., Ding, C., Tian, Z., et al. (2015). Dopamine inhibits the function of Gr-1+CD115+ myeloid-derived suppressor cells through D1-like receptors and enhances anti-tumor immunity. J. Leukoc. Biol. 97, 191–200. doi: 10.1189/jlb.5A1113-626RR

Xie, L., Moroi, Y., Tsuji, G., Liu, M., Hayashida, S., Takahara, M., et al. (2010). CD10-bearing fibroblast inhibits matrigel invasive potency of interleukin-1alpha-producing squamous cell carcinoma by diminishing substance P levels in the tumor microenvironment. Cancer Sci. 101, 2570–2578. doi: 10.1111/j.1349-7006.2010.01735.x

Yan, C., and Richmond, A. (2020). Th9 and Th17 cells: the controversial twins in cancer immunity. J. Clin. Invest. 130, 3409–3411. doi: 10.1172/JCI138418

Yan, Y., Jiang, W., Liu, L., Wang, X., Ding, C., Tian, Z., et al. (2015). Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 160, 62–73. doi: 10.1016/j.cell.2014.11.047

Yang, M. W., Tao, L. Y., Yang, Y. S., Yang, J. Y., Huo, Y. M., Liu, D. J., et al. (2020). Perineural invasion reprograms the immune microenvironment through cholinergic signaling in pancreatic ductal adenocarcinoma. Cancer Res. 80, 1991–2003. doi: 10.1158/0008-5472.CAN-19-2689
Liang et al. Neurotransmitters in TME of PC

Yang, Q., Yan, C., Yin, C., and Gong, Z. (2017). Serotonin activated hepatic stellate cells contribute to sex disparity in hepatocellular carcinoma. Cell. Mol. Gastroenterol. Hepatol. 3, 484–499. doi: 10.1016/j.ccmgh.2017.01.002

Yin, J., Albert, R. H., Tretiakova, A. P., and Jameson, B. A. (2006). 5-HT(1B) receptors play a prominent role in the proliferation of T-lymphocytes. J. Neuroimmunol. 181, 68–81. doi: 10.1016/j.jneuroim.2006.08.004

Yu, L. J., Wall, B. A., Wangari-Talbot, J., and Chen, S. (2017). Metabotropic glutamate receptors in cancer. Neuropharmacology 115, 193–202. doi: 10.1016/j.neuropharm.2016.02.011

Zahalka, A. H., Arnal-Estape, A., Maryanovich, M., Nakahara, F., Cruz, C. D., Finley, L. W. S., et al. (2017). Adrenergic nerves activate an angio-metabolic switch in prostate cancer. Science 358, 321–326. doi: 10.1126/science.aah5072

Zahalka, A. H., and Frenette, P. S. (2020). Nerves in cancer. Nat. Rev. Cancer 20, 143–157. doi: 10.1038/s41568-019-0237-2

Zaidi, Z. F., and Matthews, M. R. (2013). Source and origin of nerve fibres immunoreactive for substance P and calcitonin gene-related peptide in the normal and chronically denervated superior cervical sympathetic ganglion of the rat. Auton. Neurosci. 173, 28–38. doi: 10.1016/j.autneu.2012.11.002

Zhang, D., Li, X., Yao, Z., Wei, C., Ning, N., and Li, J. (2014). GABAergic signaling facilitates breast cancer metastasis by promoting ERK1/2-dependent phosphorylation. Cancer Lett. 348, 100–108. doi: 10.1016/j.canlet.2014.03.006

Zhang, Y., Lazarus, J., Steele, N. G., Yan, W., Lee, H. J., Nwosu, Z. C., et al. (2020). Regulatory T-cell Depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. Cancer Discov. 10, 422–439. doi: 10.1158/2159-8290.CD-19-0958

Zhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F. M., Flannagan, K., et al. (2017). Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut 66, 124–136. doi: 10.1136/gutjnl-2016-312078

Zhao, C. M., Hayakawa, Y., Kodama, Y., Muthupalani, S., Westphalen, C. B., Andersen, G. T., et al. (2014). Denervation suppresses gastric tumorigenesis. Sci. Transl. Med. 6:250ra115. doi: 10.1126/scitranslmed.3009569

Zhou, Z. (1993). [A study of CGRP receptor and its effect on the growth of human pancreatic carcinoma cells]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 15, 427–432.

Zhu, Y., Herndon, J. M., Sojka, D. K., Kim, K. W., Knolhoff, B. L., Zuo, C., et al. (2017). Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity 47, 323–338.e6. doi: 10.1016/j.immuni.2017.07.014

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Liang, Li, Gan and Tu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.